Biochemical and Pharmacological Studies on Kynurenic Acid Metabolism in the

Halina Baran, Carina Kronsteiner

Abstract read

In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Halina BaranKarl Landsteiner Research Institute for Neurochemistry, Neuropharmacology, Neurorehabilitation and Pain Treatment Mauer, Neuropsychiatric Hospital Mauer, Hausmenninger Straße 221, 3362 Mauer bei Amstetten, Austria.ORCID 0000-0001-6236-4019

Carina KronsteinerKarl Landsteiner Research Institute for Neurochemistry, Neuropharmacology, Neurorehabilitation and Pain Treatment Mauer, Neuropsychiatric Hospital Mauer, Hausmenninger Straße 221, 3362 Mauer bei Amstetten, Austria.

Funding

Department of Science and Research of the Government of Lower Austria in St. Pölten K3-F-995/001-2021

6 · The paper itself

Abstract

Kynurenic acid (KYNA), a metabolite of the L-kynurenine pathway of L-tryptophan degradation, is an endogenous blocker of glutamate ionotropic excitatory amino acid (EAA) receptors and nicotinic acetylcholine receptors (nAChRs). KYNA plays a significant role in various neuropsychiatric disorders and the aging process. Some researchers have suggested that KYNA may contribute to memory impairment. In this study, we examined the impact of L-kynurenine (a KYNA substrate) and the anti-dementia drugs D-cycloserine and Cerebrolysin on kynurenine aminotransferase (KAT) activity, an enzyme forming KYNA, in liver homogenates of

Indexed as

Helix, SnailsKynurenic AcidLearningMemoryAmino AcidsAnimalsCycloserineKynurenineLiverTransaminasesAmino AcidscerebrolysinCycloserineKynurenic AcidKynureninekynurenine-oxoglutarate transaminaseTransaminasesCerebrolysinCNSD-cycloserinegangliaGPR-35heartHelix pomatiaKATkynurenic acidliverL-kynureninenAChRNMDA receptorsnail model of learning and memorytentacle lowering

Identifiers

PMID42072724

DOI10.3390/biom16040603

PMCPMC13115359

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.